Clinical laboratory effects prolonged therapy sulfasalazine gold penicillamine effects disease duration treatment response Serial observations years clinical score subjective global assessment serum C-reactive protein CRP erythrocyte sedimentation rate ESR groups patients active rheumatoid arthritis RA treatment second line drug groups patients women men sulfasalazine SAS patients women men sodium aurothiomalate gold patients women men penicillamine groups respects gold group proportion women shorter median disease duration median CRP groups penicillamine group proportion seropositive patients group significant improvements clinical score CRP ESR time points months improvements longer months SAS SAS gold groups differences drugs months consequence number patients drug potencies mean ESR CRP levels mm/h mg/l Response treatment duration months clinical score improvement months ESR fall mm/h months criteria patients response rates SAS gold 